Johnson & Johnson
137
16
20
71
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
5.1%
7 terminated/withdrawn out of 137 trials
91.0%
+4.4% vs industry average
23%
32 trials in Phase 3/4
20%
14 of 71 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (137)
CASTLE-HFpEF (Catheter Ablation for Atrial Fibrillation Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction)
Role: collaborator
Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional Blunting
Role: collaborator
REal World MAIA UK OutcomEs
Role: collaborator
Manual Arthroplasty Versus VELYS Robotic-Assisted Solution Functional Alignment Arthroplasty for Knee Osteoarthritis
Role: collaborator
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
Role: collaborator
Echocardiographic Assessment of the Effect of Impella on Biventricular Function
Role: collaborator
Teclistamab In Waldenstrom's Macroglobulinemia
Role: collaborator
A Prospective, Single-Arm Clinical Evaluation of Visual, Refractive, and Patient-Reported Outcomes Following Bilateral Implantation of the TECNIS PureSee™ Extended Depth of Focus Intraocular Lens
Role: collaborator
Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support
Role: collaborator
Pilot Study of Biopsy Scanner for Evaluation of Bronchoscopic Small Biopsy Specimens to Determine Adequacy
Role: collaborator
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
Role: collaborator
A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
Role: collaborator
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Role: collaborator
A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease
Role: collaborator
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Role: collaborator
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
Role: collaborator
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Role: collaborator
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Role: collaborator
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Role: collaborator
Workflow Optimization During Pulse Field Ablation for Atrial Fibrillation
Role: collaborator